Human PlGF Antibody

Catalog #: MAB11199 Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
MAB11199-100
MAB11199-SP

All PlGF Antibodies

Product Details

Reviews

Summary Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human PlGF Antibody Summary

Species Reactivity

Human

Specificity

Detects human PIGF-1,2,3 and 4 in direct ELISAs.

Source

Monoclonal Mouse IgG_2A Clone # 1038928

Purification

Protein A or G purified from hybridoma culture supernatant

Immunogen

CHO-derived human PlGF-2 protein

Leu19-Arg170
Accession # NP_002623

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Label

Unconjugated

Applications

Recommended Concentration

Sample

ELISA

This antibody functions as an ELISA capture antibody when paired with human anti-PlGF-2 Monoclonal Antibody (Catalog # MAB111991).This product is intended for assay development on various assay platforms requiring antibody pairs.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: PlGF

Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines (1 ‑ 3). Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF‑1), 152 (PlGF‑2), and 203 (PlGF‑3) amino acids (aa) respectively (1 ‑ 3). Only PlGF‑2 contains a highly basic heparin‑binding 21 aa insert at the C‑terminus (1). In the mouse, only one PlGF that is the equivalent of human PlGF‑2 has been identified (3). Human PlGF‑2 shares 60%, 56%, 82%, 95% and 95% aa identity with mouse, rat, canine, equine and porcine PlGF‑2. PlGF is mainly found as a variably glycosylated, secreted, 55 ‑ 60 kDa disulfide linked homodimer (4). Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells (1, 5 ‑ 7). Circulating PlGF increases during pregnancy, reaching a peak in mid‑gestation; this increase is attenuated in preeclampsia (8). However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia (9). PlGF binds and signals through VEGF R1/Flt‑1, but not VEGF R2/Flk‑1/KDR, while VEGF binds both, but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, resulting in a PlGF inhibition of VEGF/VEGF R1 binding coupled to a subsequent promotion of VEGF/VEGF R2‑mediated angiogenesis (1, 5, 9, 10). However, PlGF (especially PlGF‑1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2 (4, 5). PlGF‑2, like VEGF164/165, shows heparin‑dependent binding of neuropilin (Npn)‑1 and Npn‑2, and can inhibit nerve growth cone collapse (11, 12). PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, and also contribute to inflammation in active sickle cell disease and atherosclerosis (6, 7, 9, 13 ‑ 16). Circulating PlGF often correlates with tumor stage and aggressiveness, and therapeutic PlGF‑2 antibodies are being investigated for their ability to inhibit tumor growth and angiogenesis (5, 13).

References

Hauser, S. and H.A. Weich (1993) Growth Factors 9:259.
Maglione, D. et al. (1993) Oncogene 8:925.
DiPalma, T. et al. (1996) Mamm. Genome 7:6.
Eriksson, A. et al. (2002) Cancer Cell 1:99.
Ribatti, D. (2008) Angiogenesis 11:215.
Oura, H. et al. (2003) Blood 101:560.
Roncal, C. et al. (2010) Cardiovasc. Res. 86:29.
Levine, R.J. et al. (2004) N. Engl. J. Med. 350:672.
Carmeliet, P. et al. (2001) Nat. Med. 7:575.
Autiero, M. et al. (2003) Nat. Med. 9:936.
Migdal, M. et al. (1998) J. Biol. Chem. 273:22272.
Cheng, L. et al. (2004) J. Biol. Chem. 279:30654.
Fischer, C. et al. (2008) Nat. Rev. Cancer 8:942.
Perelman, N. et al. (2003) Blood 102:1506.
Cianfarani, F. et al. (2006) Am. J. Pathol. 169:1167.
Maes, C. et al. (2006) J. Clin. Invest. 116:1230.

Long Name

Placenta Growth Factor

Entrez Gene IDs

5228 (Human); 18654 (Mouse)

Alternate Names

D12S1900; PGF; PGFL; placenta growth factor; placental growth factor; placental growth factor, vascular endothelial growth factor-related protein; PlGF; PlGF-2; PLGFplacental growth factor-like; SHGC-10760